NEW YORK – Immunis.AI has closed a $10 million fundraising round, bringing its total financing to $40 million to date and met several key development milestones, including three pivotal studies of the Intelligentia liquid biopsy platform, the company announced on Wednesday.
The Intelligentia platform is designed to detect and grade early-stage cancers and other disorders via disease-specific biomarkers found in blood samples. It also assays for biomarkers of patients' immune response to disease.
The additional funding will support the validation and commercialization of the company's prostate cancer molecular test, as well as the continued development of tests for breast, colon, and lung cancers, among others.
Immunis.AI, formerly known as OncoCell MDx, had previously considered launching its prostate cancer surveillance laboratory-developed test in early 2021, following an independent validation study aimed for that same time period and fueled by a $22 million Series B financing round.
The global COVID-19 pandemic had affected sample collection, timing, and workflow related to that study. The company said via email that it has now completed enrollment and product analysis is underway. Immunis.AI now anticipates launching its test in late 2022.
"Immunis has developed a platform that harnesses the power of the immune system, achieving potent signal enrichment using proprietary methods and advanced machine learning," Harry Stylli, executive chairperson of the board at Immunis.AI. "With the recently achieved major milestones, the company is poised to deliver on its core mission to improve early detection and patient outcomes."